Conjunctival sac flora and drug susceptibility analysis in normal children in East China.
Conjunctival sac flora
Drug susceptibility
Normal children
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
02 Jun 2023
02 Jun 2023
Historique:
received:
05
09
2022
accepted:
24
05
2023
medline:
5
6
2023
pubmed:
3
6
2023
entrez:
2
6
2023
Statut:
epublish
Résumé
To investigate the distribution characteristics of conjunctival sac flora and assess the susceptibility of commonly used topical antimicrobial agents in normal children under the age of 18 in East China. In 2019, a study was conducted at Qingdao Eye Hospital of Shandong First Medical University to analyze the microorganism cultures of conjunctival sac in 1258 normal children (2516 eyes; average age, 6.21 ± 3.78 years) in East China. Exclusion criteria included children with ocular surface diseases and those who had used any topical antimicrobial agents recently. The microorganism species in the conjunctival sac were analyzed using the M-38A protocol (microdilution method; investigators read the minimum inhibitory concentration [MIC] values) by the Clinical and Laboratory Standards Institute to determine drug susceptibility. The incidence of conjunctival sac microorganism in children was 32.87% (827/2516), a total of 541 cases (male 293, female 248). Children with conjunctival sac flora in a single eye were 255 and in both eyes were 286 (no statistical difference, P > 0.05). The concordance rate of children with binocular conjunctival sac flora was 32.16% (174/541; male 84, female 90). A total of 42 species of bacteria were detected. Children with Gram-positive cocci accounted for the highest proportion, 91.54% (757/827). The top three bacteria with the highest detection rates were Staphylococcus epidermidis (S. epidermidis; 52.12%), Streptococcus (12.09%), and Staphylococcus aureus (S. aureus; 10.76%). Streptococcus mitis (5.20%) accounted for the highest proportion of Streptococcus.S. epidermidis had the highest proportion in all age groups and was positively correlated with age (r = 0.89, P = 0.03). Before six years of age, the streptococcal proportion(mainly S. mitis) was greater than that of Staphylococcus aureus. The drug susceptibility analysis showed that S. epidermidis was most sensitive to gatifloxacin (98.61%), while it had the highest resistance rate to erythrocin (87.94%). S. aureus had the highest susceptibility to moxifloxacin (100%). Streptococcus was most sensitive to moxifloxacin (96.97%) and had the highest resistance rate to tobramycin (92.93%). Conjunctival sac flora in children was dominated by Gram-positive cocci, mainly S. epidermidis, S. aureus, and Streptococcus. S. epidermidis increased with age; the proportion of Streptococcus was higher than S. aureus among children aged 0-6 years. The typical conjunctiva sac flora was generally sensitive to quinolones, such as moxifloxacin and gatifloxacin; Streptococcus displayed high resistance to tobramycin antibiotics; and the female children had higher resistance to tobramycin than the male children.
Identifiants
pubmed: 37268920
doi: 10.1186/s12886-023-02995-1
pii: 10.1186/s12886-023-02995-1
pmc: PMC10239125
doi:
Substances chimiques
Gatifloxacin
L4618BD7KJ
Moxifloxacin
U188XYD42P
Anti-Bacterial Agents
0
Tobramycin
VZ8RRZ51VK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
248Informations de copyright
© 2023. The Author(s).
Références
BMC Pediatr. 2020 Jun 22;20(1):306
pubmed: 32571257
BMC Infect Dis. 2019 Sep 3;19(1):768
pubmed: 31481023
Clin Ophthalmol. 2017 Jan 27;11:237-241
pubmed: 28203050
J Curr Ophthalmol. 2018 Apr 10;30(4):348-352
pubmed: 30555969
Invest Ophthalmol Vis Sci. 2016 Oct 01;57(13):5116-5126
pubmed: 27699405
Nepal J Ophthalmol. 2016 Jan;8(15):23-35
pubmed: 28242882
Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1919-1922
pubmed: 27067874
Chem Immunol Allergy. 2007;92:36-49
pubmed: 17264481
BMJ Open. 2016 May 09;6(5):e010733
pubmed: 27160843
Brain Res Bull. 2010 Feb 15;81(2-3):219-28
pubmed: 19828129
J Clin Med. 2022 Feb 21;11(4):
pubmed: 35207407
Ophthalmologe. 2018 Aug;115(8):697-706
pubmed: 29802422
Front Physiol. 2017 May 31;8:363
pubmed: 28620316
J Antimicrob Chemother. 2015 Feb;70(2):416-9
pubmed: 25313205
Front Med (Lausanne). 2022 Mar 08;9:841112
pubmed: 35350577
BMC Ophthalmol. 2017 Nov 25;17(1):212
pubmed: 29178851
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5616-23
pubmed: 18055811
J Ocul Pharmacol Ther. 2014 Dec;30(10):815-22
pubmed: 25244402